Worth reading
54Recurring
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
276
¥ millions (expected proceeds if all rights are exercised)Wording
Conditional
How definitive the wording is.Details of issuance or disposal
Progress report regarding the effectiveness of the mandatory exercise provision for paid stock options (7th Series Stock Acquisition Rights)
発行・処分する株式数
20,500 remaining stock acquisition rights, representing 2,050,000 underlying shares (as of today)
Intended allottee
Name Representative Director and President Hisanaga Kengo (久永賢剛) / Category Representative Director and President / Number remaining 5,300, Name Hirose Takuya (廣瀬卓也) / Category Directors / Number remaining 3,800, Name Seki Takanori (関孝徳) / Category Directors / Number remaining 3,800, Name Shitaoka Hiroshi (下岡寛) / Category Directors / Number remaining 3,800, Name Fukuda Ken (福田健) / Category Directors / Number remaining 3,800, Name Hanaoka Masamichi (花岡正道) / Category Audit and Supervisory Committee Member / Number remaining 0 rights
Issue price: ¥228 per share
Amount of funds to be raised
Total proceeds: approximately ¥276 million (expected if all rights are exercised); estimated net proceeds: Not disclosed
Specific use of funds
Working capitalAmount Specific allocation has not been determined
発行済株式総数
1.17% (if all rights are exercised)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥135. Adjustment provision for the exercise price: Not disclosed
Exercise period
5 September 2025 to 4 September 2027
Number of Stock Acquisition Rights
Total issued: 21,520; remaining: 20,500 (as of today)
Categories and Number of Persons Covered
1 Representative Director and President, 4 Directors and 1 Audit and Supervisory Committee Member (number of eligible persons at allocation). Remaining rights: 1 Representative Director and President, 4 Directors and 0 Audit and Supervisory Committee Members
Most recent equity financing
Timing Resolution on 18 August 2025; allocation on 4 September 2025 / Type Paid stock options (7th Series Stock Acquisition Rights) / Amount Issue price: ¥228 per share
| Item | Details |
|---|---|
| Type of issuance or disposal | Progress report regarding the effectiveness of the mandatory exercise provision for paid stock options (7th Series Stock Acquisition Rights) |
| Number of shares to be issued or disposed of | 20,500 remaining stock acquisition rights, representing 2,050,000 underlying shares (as of today) |
| Issue price and disposal price | Issue price: ¥228 per share |
| Amount of funds to be raised | Total proceeds: approximately ¥276 million (expected if all rights are exercised); estimated net proceeds: Not disclosed |
| Specific use of funds | Details Working capital / Amount Specific allocation has not been determined / Scheduled timing of expenditures Not disclosed |
| Intended allottee | Name Representative Director and President Hisanaga Kengo (久永賢剛) / Category Representative Director and President / Number remaining 5,300, Name Hirose Takuya (廣瀬卓也) / Category Directors / Number remaining 3,800, Name Seki Takanori (関孝徳) / Category Directors / Number remaining 3,800, Name Shitaoka Hiroshi (下岡寛) / Category Directors / Number remaining 3,800, Name Fukuda Ken (福田健) / Category Directors / Number remaining 3,800, Name Hanaoka Masamichi (花岡正道) / Category Audit and Supervisory Committee Member / Number remaining 0 rights |
| Dilution Rate | 1.17% (if all rights are exercised) |
| Exercise price | ¥135. Adjustment provision for the exercise price: Not disclosed |
| Exercise period | 5 September 2025 to 4 September 2027 |
| Number of Stock Acquisition Rights | Total issued: 21,520; remaining: 20,500 (as of today) |
| Categories and Number of Persons Covered | 1 Representative Director and President, 4 Directors and 1 Audit and Supervisory Committee Member (number of eligible persons at allocation). Remaining rights: 1 Representative Director and President, 4 Directors and 0 Audit and Supervisory Committee Members |
| Most recent equity financing | Timing Resolution on 18 August 2025; allocation on 4 September 2025 / Type Paid stock options (7th Series Stock Acquisition Rights) / Amount Issue price: ¥228 per share |
Items this document does not state (16)
Total issue valueEstimated issuance expensesPayment dateIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the closing price of the Company's shares remained below ¥67.5, which is 50% of the ¥135 exercise price, for the 5 consecutive trading days from 15 June 2026 through 19 June 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.